GlassScriptPhysician profile
Laura Williams
NPI 1710432109
$2,786.71
in general payments reported to CMS, 2019-2025
30 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $523 · 2022: $749 · 2023: $877 · 2024: $469 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $714.53 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $326.04 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Electromed, INC. | $245.29 | 2022-2023 | Smartvest |
| Mylan Specialty L.P. | $238.23 | 2021-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $162.70 | 2021-2024 | Breztri, Airsupra |
| Amgen INC. | $157.41 | 2022-2024 | Repatha, Otezla, Prolia |
| Abbvie INC. | $91.68 | 2023-2025 | |
| Lilly USA, LLC | $89.03 | 2022-2024 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $84.08 | 2025 | Myfembree, Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.90 | 2023-2024 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $60.13 | 2022-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $53.20 | 2021-2023 | Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $52.64 | 2022-2024 | Eliquis |
| Shield Therapeutics INC | $44.99 | 2023-2024 | Accrufer |
| Pfizer INC. | $43.56 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.30 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $39.41 | 2022-2023 | Watchman Flx |
| Dexcom, INC. | $36.21 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $34.57 | 2022-2025 | |
| Inspire Medical Systems, INC. | $27.18 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $20.84 | 2022 | |
| Eisai INC. | $20.09 | 2021 | |
| Biogen, INC. | $18.98 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $17.66 | 2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.35 | 2021 | |
| Aurinia Pharma U.S., INC. | $15.99 | 2022 | |
| Amarin Pharma, INC. | $14.58 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.33 | 2022 | |
| Genentech USA, INC. | $14.23 | 2021 | |
| Millicent US INC | $13.58 | 2024 | Intrarosa, Femring |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.